Back

SGLT2 inhibitors promote electrical remodeling in heart failure patients undergoing cardiac resynchronization therapy: a clinical and metabolomic analysis

30 March 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Cardiac resynchronisation therapy Cardiac Resynchronisation Therapy (CRT) EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Gianmarco Arabia

Spedali Civili, University Of Brescia, Brescia (Italy)

4 More presentations in this session

Presentation thumbnail
In CRT candidates, left septal myocardial capture in close proximity to the left bundle branch provides the same LV work effectivity and left ventricular synchrony as direct left bundle branch pacing
Mr L. Poviser (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
Six-month echocardiographic follow-up of left bundle branch optimized cardiac resynchronization therapy (LOT-CRT) versus traditional CRT
Professor P. Vijayaraman (Wilkes Barre, US)
Abstract Slides Video
Presentation thumbnail
AV block occurrence in normal AV conduction CRT fusion pacing: single center experience
Doctor A. Faur (Timisoara, RO)
Abstract Slides Video
Presentation thumbnail
Left ventricle lead placement in areas with a higher CART score, indicating late mechanical activation, is associated with greater response in cardiac resynchronisation therapy patients
Mr W. Gerrits (Utrecht, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac resynchronisation therapy

The Event

Event poster

EHRA 2025

30 March - 1 April 2025
You may be interested in
thumbnail
Congress Presentation
Impact of SLGT2 inhibitors treatment initiation on the reduction of atrial and ventricular arrhythmias in patients with implanted cardiac defibrillator
thumbnail
Congress Presentation
Deformation Imaging by Strain in Chronic heart failure Over gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 inhibitors (DISCOVER SGLT2i)
thumbnail
Congress Presentation
Cardiac reverse remodeling after SGLT2 inhibitor therapy: exploring beyond sex differences

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources